IN ADULTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA REDEFINE THEIR STORYLINE

Man holding graph line.
Man holding graph line.

Primary analysis1,4

87% ORR (n=52/60) • Median study follow-up: 12.3 months
DEEP 62% CR (n=37/60)

~3-year analysis*

DURABLE 36.5 months mDOR2,3† (n=52; 95% Cl: 14.4, 47.1) at a median study follow-up of 35.6 months
62% alive at 3 years5 (Estimated 3-year OS rate; 95% CI: 49, 74)
OS was a secondary endpoint of the ZUMA-2 study. OS data are descriptive, not included in the USPI, and should be carefully interpreted. In the primary analysis, mOS was not reached at a median study follow-up of 12.3 months.4

BTKi=Bruton’s tyrosine kinase inhibitor; CAR=chimeric antigen receptor; CD=cluster of differentiation; CI=confidence interval; CR=complete response; DOR=duration of response; MCL=mantle cell lymphoma; mDOR=median duration of response; mOS=median overall survival; ORR=objective response rate; OS=overall survival; PFS=progression-free survival; R/R=relapsed or refractory; USPI=US Prescribing Information.

References: 1. TECARTUS® (brexucabtagene autoleucel). Prescribing information. Kite Pharma, Inc; 2024. 2. Data on file [1]. Kite Pharma, Inc; 2022. 3. Data on file [2]. Kite Pharma, Inc; 2022. 4. Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle cell lymphoma. N Engl J Med. 2020;382(14):1331-1342. 5. Data on file [3]. Kite Pharma, Inc; 2022. 6. Data on file [4]. Kite Pharma, Inc; 2022.